Switch theme
Sign up to access all valuation multiples
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
2009
n/a
LTM Revenue $261M
LTM EBITDA $105M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sinopep has a last 12-month revenue (LTM) of $261M and a last 12-month EBITDA of $105M.
In the most recent fiscal year, Sinopep achieved revenue of $226M and an EBITDA of $94.8M.
Sinopep expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sinopep valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $261M | XXX | $226M | XXX | XXX | XXX |
| Gross Profit | $171M | XXX | $153M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $105M | XXX | $94.8M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 42% | XXX | XXX | XXX |
| EBIT | $72.0M | XXX | $72.9M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $64.9M | XXX | $56.1M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $127M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sinopep's stock price is CNY 48 (or $7).
Sinopep has current market cap of CNY 10.8B (or $1.5B), and EV of CNY 11.9B (or $1.6B).
See Sinopep trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.5B | XXX | XXX | XXX | XXX | $0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sinopep has market cap of $1.5B and EV of $1.6B.
Sinopep's trades at 7.3x EV/Revenue multiple, and 17.4x EV/EBITDA.
Equity research analysts estimate Sinopep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sinopep has a P/E ratio of 23.1x.
See valuation multiples for Sinopep and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | 15.7x | XXX | 17.4x | XXX | XXX | XXX |
| EV/EBIT | 22.9x | XXX | 22.6x | XXX | XXX | XXX |
| EV/Gross Profit | 9.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.1x | XXX | 26.7x | XXX | XXX | XXX |
| EV/FCF | -17.3x | XXX | -17.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSinopep's last 12 month revenue growth is 35%
Sinopep's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Sinopep's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sinopep's rule of X is 127% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sinopep and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 35% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 63% | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 77% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 127% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sinopep acquired XXX companies to date.
Last acquisition by Sinopep was XXXXXXXX, XXXXX XXXXX XXXXXX . Sinopep acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sinopep founded? | Sinopep was founded in 2009. |
| Where is Sinopep headquartered? | Sinopep is headquartered in China. |
| Is Sinopep publicy listed? | Yes, Sinopep is a public company listed on SHG. |
| What is the stock symbol of Sinopep? | Sinopep trades under 688076 ticker. |
| When did Sinopep go public? | Sinopep went public in 2021. |
| Who are competitors of Sinopep? | Similar companies to Sinopep include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Sinopep? | Sinopep's current market cap is $1.5B |
| What is the current revenue of Sinopep? | Sinopep's last 12 months revenue is $261M. |
| What is the current revenue growth of Sinopep? | Sinopep revenue growth (NTM/LTM) is 35%. |
| What is the current EV/Revenue multiple of Sinopep? | Current revenue multiple of Sinopep is 6.3x. |
| Is Sinopep profitable? | Yes, Sinopep is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sinopep? | Sinopep's last 12 months EBITDA is $105M. |
| What is Sinopep's EBITDA margin? | Sinopep's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of Sinopep? | Current EBITDA multiple of Sinopep is 15.7x. |
| What is the current FCF of Sinopep? | Sinopep's last 12 months FCF is -$95.5M. |
| What is Sinopep's FCF margin? | Sinopep's last 12 months FCF margin is -37%. |
| What is the current EV/FCF multiple of Sinopep? | Current FCF multiple of Sinopep is -17.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
